/STOK
STOK Stock - Stoke Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$31.96+0.09%
+$0.03 (+0.09%) • Dec 19
83
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+27.5%upside
Target: $40.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STOK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$31.64 – $32.28
TARGET (TP)$40.75
STOP LOSS$29.40
RISK/REWARD1:3.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$38.69
52W Low$5.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $36.55M | $8.78M | $12.40M | N/A | N/A |
| Gross Profit | $36.55M | $8.78M | $12.40M | N/A | $-1,926,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-101,372,000 | $-114,773,000 | $-104,356,000 | $-86,065,000 | $-53,044,000 |
| Net Income | $-88,981,000 | $-104,699,000 | $-101,067,000 | $-85,805,000 | $-52,243,000 |
| Net Margin | -243.4% | -1192.5% | -814.7% | N/A | N/A |
| EPS | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 |
Company Overview
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
67%
Hold / Neutral
2
22%
Sell / Underperform
1
11%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$21
Average Target
↓ 34.3% Downside
Now
$9
Low
$21
Average
$30
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 18th 2025 | Jefferies | Initiation | Buy | $30 |
| December 20th 2024 | Chardan Capital Markets | Initiation | Buy | $24 |
| October 14th 2024 | Leerink Partners | Resumed | Outperform | $18 |
| March 26th 2024 | TD Cowen | Upgrade | Outperform | - |
| November 20th 2023 | JP Morgan | Resumed | Neutral | - |
| July 25th 2023 | TD Cowen | Downgrade | Market Perform | - |
| May 1st 2023 | BofA Securities | Upgrade | Neutral | $12← $9 |
| April 26th 2023 | Canaccord Genuity | Resumed | Buy | $24 |
| January 6th 2023 | BofA Securities | Downgrade | Underperform | $9← $22 |
| October 24th 2022 | SVB Leerink | Upgrade | Outperform | $30 |
Earnings History & Surprises
STOKBeat Rate
67%
Last 18 quarters
Avg Surprise
+30.0%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
+3.2%
$-0.60vs$-0.62
Q2 24
+5.0%
$-0.57vs$-0.60
Q3 24
+19.3%
$-0.46vs$-0.57
Q4 24
+9.6%
$-0.47vs$-0.52
Q1 25
+64.7%
$-0.18vs$-0.51
Q2 25
+613.5%
$1.90vs$-0.37
Q3 25
+29.8%
$-0.40vs$-0.57
Q4 25
-20.4%
$-0.65vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.74 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.54 | $-0.65 | -20.4% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.57 | $-0.40 | +29.8% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.37 | $1.90 | +613.5% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.51 | $-0.18 | +64.7% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.52 | $-0.47 | +9.6% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.57 | $-0.46 | +19.3% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.60 | $-0.57 | +5.0% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.62 | $-0.60 | +3.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.65 | $-0.55 | +15.4% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.65 | $-0.69 | -6.2% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.70 | $-0.53 | +24.3% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.72 | $-0.65 | +9.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.69 | $-0.66 | +4.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.70 | $-0.63 | +10.0% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.61 | $-0.66 | -208.2% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.62 | $-0.66 | -6.5% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.58 | $-0.61 | -5.2% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.49 | $-0.60 | -22.4% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Dec 15, 2025, 01:59 PM
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $32
📈 PositiveBenzinga•Nov 5, 2025, 02:23 PM
Stoke Therapeutics shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 5, 2025, 02:20 PM
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target
📈 PositiveBenzinga•Nov 5, 2025, 10:15 AM
Stoke Therapeutics Q3 EPS $(0.65) Misses $(0.59) Estimate, Sales $10.632M Beat $5.511M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 09:02 PM
JP Morgan Maintains Neutral on Stoke Therapeutics, Raises Price Target to $25
➖ NeutralBenzinga•Nov 3, 2025, 03:53 PM
Stoke Therapeutics Unveils Two-Year Data Offering Hope For Patients With Rare Genetic Vision Disorder
📈 PositiveBenzinga•Oct 20, 2025, 11:36 AM
Needham Maintains Buy on Stoke Therapeutics, Raises Price Target to $35
📈 PositiveBenzinga•Oct 10, 2025, 10:22 AM
Stoke Therapeutics Names Ian F. Smith CEO
➖ NeutralBenzinga•Oct 6, 2025, 11:36 AM
Frequently Asked Questions about STOK
What is STOK's current stock price?
Stoke Therapeutics, Inc. (STOK) is currently trading at $31.96 per share. The stock has moved +0.09% today.
What is the analyst price target for STOK?
The average analyst price target for STOK is $40.75, based on 1 analyst.
What sector is Stoke Therapeutics, Inc. in?
Stoke Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is STOK's market cap?
Stoke Therapeutics, Inc. has a market capitalization of $1.83 billion, making it a small-cap company.
Does STOK pay dividends?
No, Stoke Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
BCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
NVAX
Novavax, Inc.
$6.66
Mkt Cap: $1.1B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to STOK for comparison